Published in Drug Law Weekly, November 28th, 2006
Revenues for the third quarter of 2006 were $8.0 million, up from $6.9 million for the third quarter of 2005, with higher amounts attributed to recognition of revenues under an agreement with the Armed Forces awarded in September 2006, relating to research activities that commenced in January 2006, as well as growth of European sales of the Intercept Blood System for platelets.
Total operating expenses for the third quarter of 2006 were $10.7 million, up from $8.8 million for the same period in 2005, primarily due to costs associated with establishing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.